ClinicalTrials.gg
CompletedNCT01765192Updated Feb 1, 2017Results posted

Roflumilast Plus Montelukast in Adults With Severe Asthma

A Phase 2 interventional study of Roflumilast and Roflumilast placebo in Asthma, sponsored by AstraZeneca. Completed at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-01.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing roflumilast in Asthma — none open to participants now, none under way, none of them phase 3. Roflumilast · Asthma.

Enrollment
7th of 10
64 · median 300
Started
2013
the only one that year
Phase 2
3 of 10
none open now
Registered
8th of 10
by date
Lead sponsor
8 of 10
AstraZeneca

Among the 10 studies testing roflumilast in Asthma, this one is the 7th largest by enrollment, is the only one that started in 2013, is one of 3 in phase 2, and was the 8th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 10 studies testing roflumilast in Asthma is open now. The open studies under Asthma, anywhere →

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing roflumilast in Asthma as a file.
02

Study summary

This study will evaluate the effect of roflumilast 500 μg once daily (QD) plus montelukast 10 mg QD versus 10 mg montelukast QD alone on predose (trough) prebronchodilator forced expiratory volume in the first second (FEV1).

Read the detailed description

The drug being tested in this study is called roflumilast. Roflumilast is being tested to treat people who have asthma. This study will look at lung function and asthma symptoms of people who take roflumilast in combination with montelukast.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements (ie, to follow clinical trial procedures and Investigator instructions adequately).
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. Has a documented physician diagnosis of severe asthma consistent with global initiative for asthma (GINA) step 4 clinical features [Gina 2011] for at least 6 months.
  4. Is male or female and aged 18 years or above.
  5. Has been treated with a fixed or free combination of at least medium-dose inhaled (ICS) (ie, ≥ 250 µg fluticasone propionate daily or equivalent ICS) plus long-acting beta agonist (LABA) for at least 3 months prior to Screening with stable ICS dose for at least 4 weeks before Visit 2.
  6. Shows GINA-defined uncontrolled asthma or an asthma control questionnaire (ACQ-7) score ≥1.5 despite at least medium dose ICS/LABA therapy within 4 weeks prior to Visit 1 (Screening).
  7. Shows a pre-bronchodilator of > 55% and ≤ 85% of predicted at Visit 1 (Screening). For participants performing induced sputum FEV1 must be in addition > 1 liter.
  8. Has airway obstruction proven to be reversible by an improvement of FEV1 of at least 12% and 200 mL after inhalation of a short-acting bronchodilator. This can be either documented in the medical history (with supporting spirometry recordings) in the previous 12 months or demonstrated during screening at Visit 1 (Screening).

Exclusion criteria

Exclusion Criteria:

  1. Has received any compound within 30 days prior to the start of the clinical trial or has participated in the active treatment phase of another clinical trial where a persisting pharmacodynamic effect of the trial treatment of that clinical trial cannot be excluded (eg, participant is well into a treatment free follow-up phase).
  2. Participation in another clinical trial during the current trial.
  3. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  4. Severe asthma exacerbation not resolved 4 weeks prior to Visit 1, (defined by the need for oral or parenteral glucocorticosteroid intake for at least 3 days and/or hospitalization or emergency room visit with the need for oral or parenteral use).
  5. Lower respiratory tract infection not resolved 4 weeks prior to Visit 1.
  6. A diagnosis of (COPD) (based on Global Initiative for Chronic Obstructive Lung Disease [GOLD] criteria) and/or other relevant forms of lung disease (eg, history of primary bronchiectasis, cystic fibrosis, idiopathic (pan)bronchiolitis or bronchiolitis obliterans, bronchopulmonary allergic aspergillosis, Churg-Strauss Syndrome, paradoxical vocal cord closure, lung resection, lung cancer, interstitial lung disease [eg, fibrosis, silicosis, sarcoidosis], or active tuberculosis) that may interfere with the evaluation of a treatment response.
  7. Current participation in a pulmonary rehabilitation program or completion of a pulmonary rehabilitation program within 3 months preceding Visit 1.
  8. Has, in the judgment of the investigator, abnormal laboratory values (hematology or biochemistry) at screening suggesting an undiagnosed disease requiring further clinical evaluation.
  9. Has severe neuropsychiatric or neurological disorders (eg, history of depression associated with suicidal thinking, suicidal ideation or behavior).
  10. Has congestive heart failure severity grade III or IV according to the .
  11. Has symptomatic ischemic heart disease (angina pectoris).
  12. Has hemodynamically significant cardiac arrhythmias or heart valve deformations.
  13. Has liver impairment, defined as B/C and/or active viral hepatitis.
  14. Has severe immunological diseases (eg, multiple sclerosis, systemic lupus erythematosus, progressive multifocal leukoencephalopathy) or known infection with (HIV).
  15. Has severe acute infectious diseases (eg, tuberculosis, or acute hepatitis).
  16. Has any diagnosis of a malignant disease (other than basal or squamous cell carcinoma) within 5 years prior to Screening Visit 1.
  17. Has a history of smoking within 1 year of Visit 1 and smoking history ≥10 pack years.
  18. Has a history of drug abuse (defined as illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 2 alcoholic drinks per day) within the past 1 year prior to the Screening visit.
  19. Has history of clinically significant allergies or idiosyncrasies to roflumilast, montelukast or any inactive ingredient(s) of these products, eg, rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption or phenylketonuria.
  20. Has known highly unstable asthma defined by severe bronchoconstriction after bronchoprovocation with isotonic saline.
  21. Females of not willing to use acceptable methods such as hormonal contraceptives (oral, injection or implant) or intrauterine contraceptive devices or who started such methods less than 2 months prior to screening or who are not willing to use a double barrier method of contraception (diaphragm plus condom).
  22. If female, is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
  23. Is required to take excluded medication.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Roflumilast plus montelukast, then placebo plus montelukast

    Participants in sequence 1 received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received placebo plus montelukast 10 mg orally once daily for 4 weeks.

    Drug: Roflumilast · Drug: Roflumilast placebo · Drug: Montelukast

  • Experimental
    Placebo plus montelukast, then roflumilast plus montelukast

    Participants in sequence 2 received placebo plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks.

    Drug: Roflumilast · Drug: Roflumilast placebo · Drug: Montelukast

Interventions

  • Roflumilast was supplied in tablets.

    Also known as: Daxas, Daliresp

  • DrugRoflumilast placebo

    Roflumilast placebo was supplied in tablets.

  • Montelukast was supplied in tablets.

    Also known as: Singulair, Pluralair

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)

    FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEV1 will be measured using spirometry in accordance with the American Thoracic Society / European Respiratory Society (ATS/ERS) consensus guidelines. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline FEV1 measurement as the covariate was used for analysis.

    Time frame: Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)

Secondary outcomes

  1. Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Vital Capacity (FVC)

    FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC will be measured using spirometry in accordance with ATS/ERS consensus guidelines. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline FVC measurement as the covariate was used for analysis.

    Time frame: Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)

  2. Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Expiratory Flow (FEF) 25-75%

    FEF is a measure of how much air can be exhaled from the lungs. It is an indicator of obstruction of the smaller airways. FEF25-75% is the mid-flow rate or forced expiratory flow occurring in the middle 50% of the patient's exhaled volume, and will be measured using spirometry in accordance with ATS/ERS consensus guidelines. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline FEF measurement as the covariate was used for analysis.

    Time frame: Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)

  3. Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Peak Expiratory Flow (PEF)

    PEF is a person's maximum speed of expiration. It measures the airflow through the bronchi and thus the degree of obstruction in the airways. PEF will be measured using spirometry in accordance with ATS/ERS consensus guidelines. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline PEF measurement as the covariate was used for analysis.

    Time frame: Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)

  4. Change From Baseline in Morning Peak Expiratory Flow (PEF)

    PEF will be measured at home using portable electronic peak flow meter. The participant will record PEF daily in the morning immediately after getting up. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline PEF measurement as the covariate was used for analysis.

    Time frame: Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)

  5. Change From Baseline in Daytime Asthma Symptoms

    Patients will assess their daily day-time asthma symptoms according to the following scale: 0: Very well, no symptoms. 1: One episode of wheezing, cough or breathlessness. 2: More than one episode of wheezing, cough or breathlessness without interfering with normal activities. 3: Wheezing, cough or short of breath most of the day which interfered to some extent with normal activities. 4: Asthma very bad. Unable to carry out daily activities as usual. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline Daytime Asthma Symptoms measurement as the covariate was used for analysis. A negative change from Baseline indicates improvement.

    Time frame: Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)

  6. Change From Baseline in Nighttime Asthma Symptoms

    Patients will assess their daily night-time asthma symptoms according to the following scale: 0: No symptoms, slept through the night. 1: Slept well but some complaints in the morning. 2: Woke up once because of asthma (inclusive early awakening). 3: Woke up several times because of asthma (inclusive early awakening). 4: Bad night, awake most of the night because of asthma. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline Nighttime Asthma Symptoms measurement as the covariate was used for analysis. A negative change from Baseline indicates improvement.

    Time frame: Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)

07

Results

Posted Jul 8, 2015

Participant flow

Participants took part in the study at 12 investigative sites in Germany, Hungary, and South Africa from 15 February 2013 to 24 October 2013.

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneRoflumilast Plus Montelukast, Then Placebo Plus MontelukastPlacebo Plus Montelukast, Then Roflumilast Plus Montelukast
Started3232
Completed3231
Not completed01
Withdrew: Adverse event01
Washout Period
Participant flow — Washout Period
MilestoneRoflumilast Plus Montelukast, Then Placebo Plus MontelukastPlacebo Plus Montelukast, Then Roflumilast Plus Montelukast
Started3231
Completed3030
Not completed21
Withdrew: Voluntary withdrawal11
Withdrew: Reason not specified10
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneRoflumilast Plus Montelukast, Then Placebo Plus MontelukastPlacebo Plus Montelukast, Then Roflumilast Plus Montelukast
Started3030
Completed3028
Not completed02
Withdrew: Reason not specified02
End of Treatment Period 2 to Final Visit
Participant flow — End of Treatment Period 2 to Final Visit
MilestoneRoflumilast Plus Montelukast, Then Placebo Plus MontelukastPlacebo Plus Montelukast, Then Roflumilast Plus Montelukast
Started3028
Completed3027
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimaryChange From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)

FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEV1 will be measured using spirometry in accordance with the American Thoracic Society / European Respiratory Society (ATS/ERS) consensus guidelines. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline FEV1 measurement as the covariate was used for analysis.

Time frame:
Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
Reported as:
Least squares mean · liters
Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
litersRoflumilast Plus MontelukastPlacebo Plus Montelukast
Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)0.18 ± 0.0280.08 ± 0.027
Statistical analysis
  • Roflumilast Plus Montelukast vs Placebo Plus Montelukast · ANCOVA · p = 0.013 · Least squares (ls) mean difference: 0.10 · 95% CI 0.0219 to 0.1795
SecondaryChange From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Vital Capacity (FVC)

FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC will be measured using spirometry in accordance with ATS/ERS consensus guidelines. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline FVC measurement as the covariate was used for analysis.

Time frame:
Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
Reported as:
Least squares mean · liters
Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Vital Capacity (FVC)
litersRoflumilast Plus MontelukastPlacebo Plus Montelukast
Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Vital Capacity (FVC)0.12 ± 0.0290.06 ± 0.027
Statistical analysis
  • Roflumilast Plus Montelukast vs Placebo Plus Montelukast · ANCOVA · p = 0.129 (P-values were obtained using an ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline pre-bronchodilator FVC measurement as the covariate.) · Ls mean difference: 0.06 · 95% CI -0.0185 to 0.1422
SecondaryChange From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Expiratory Flow (FEF) 25-75%

FEF is a measure of how much air can be exhaled from the lungs. It is an indicator of obstruction of the smaller airways. FEF25-75% is the mid-flow rate or forced expiratory flow occurring in the middle 50% of the patient's exhaled volume, and will be measured using spirometry in accordance with ATS/ERS consensus guidelines. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline FEF measurement as the covariate was used for analysis.

Time frame:
Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
Reported as:
Least squares mean · liters/second
Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Expiratory Flow (FEF) 25-75%
liters/secondRoflumilast Plus MontelukastPlacebo Plus Montelukast
Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Expiratory Flow (FEF) 25-75%0.23 ± 0.0390.11 ± 0.039
Statistical analysis
  • Roflumilast Plus Montelukast vs Placebo Plus Montelukast · ANCOVA · p = 0.032 (P-values were obtained using an ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline pre-bronchodilator FEF measurement as the covariate.) · Ls mean difference: 0.12 · 95% CI 0.0113 to 0.2364
SecondaryChange From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Peak Expiratory Flow (PEF)

PEF is a person's maximum speed of expiration. It measures the airflow through the bronchi and thus the degree of obstruction in the airways. PEF will be measured using spirometry in accordance with ATS/ERS consensus guidelines. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline PEF measurement as the covariate was used for analysis.

Time frame:
Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
Reported as:
Least squares mean · liters/minute (L/min)
Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Peak Expiratory Flow (PEF)
liters/minute (L/min)Roflumilast Plus MontelukastPlacebo Plus Montelukast
Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Peak Expiratory Flow (PEF)15.05 ± 10.6167.85 ± 10.401
Statistical analysis
  • Roflumilast Plus Montelukast vs Placebo Plus Montelukast · ANCOVA · p = 0.635 (P-values were obtained using an ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline pre-bronchodilator PEF measurement as the covariate.) · Ls mean difference: 7.21 · 95% CI -23.0531 to 37.4660
SecondaryChange From Baseline in Morning Peak Expiratory Flow (PEF)

PEF will be measured at home using portable electronic peak flow meter. The participant will record PEF daily in the morning immediately after getting up. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline PEF measurement as the covariate was used for analysis.

Time frame:
Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
Reported as:
Least squares mean · L/min
Change From Baseline in Morning Peak Expiratory Flow (PEF)
L/minRoflumilast Plus MontelukastPlacebo Plus Montelukast
Change From Baseline in Morning Peak Expiratory Flow (PEF)20.85 ± 3.7087.23 ± 3.646
Statistical analysis
  • Roflumilast Plus Montelukast vs Placebo Plus Montelukast · ANCOVA · p = 0.011 (P-values were obtained using an ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline pre-bronchodilator PEF measurement as the covariate.) · Ls mean difference: 13.62 · 95% CI 3.1896 to 24.0553
SecondaryChange From Baseline in Daytime Asthma Symptoms

Patients will assess their daily day-time asthma symptoms according to the following scale: 0: Very well, no symptoms. 1: One episode of wheezing, cough or breathlessness. 2: More than one episode of wheezing, cough or breathlessness without interfering with normal activities. 3: Wheezing, cough or short of breath most of the day which interfered to some extent with normal activities. 4: Asthma very bad. Unable to carry out daily activities as usual. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline Daytime Asthma Symptoms measurement as the covariate was used for analysis. A negative change from Baseline indicates improvement.

Time frame:
Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Daytime Asthma Symptoms
units on a scaleRoflumilast Plus MontelukastPlacebo Plus Montelukast
Change From Baseline in Daytime Asthma Symptoms-0.39 ± 0.061-0.18 ± 0.063
Statistical analysis
  • Roflumilast Plus Montelukast vs Placebo Plus Montelukast · ANCOVA · p = 0.025 (P-values were obtained using an ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline Daytime Asthma Symptom Score as the covariate.) · Ls mean difference: -0.21 · 95% CI -0.3850 to -0.0271
SecondaryChange From Baseline in Nighttime Asthma Symptoms

Patients will assess their daily night-time asthma symptoms according to the following scale: 0: No symptoms, slept through the night. 1: Slept well but some complaints in the morning. 2: Woke up once because of asthma (inclusive early awakening). 3: Woke up several times because of asthma (inclusive early awakening). 4: Bad night, awake most of the night because of asthma. An ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline Nighttime Asthma Symptoms measurement as the covariate was used for analysis. A negative change from Baseline indicates improvement.

Time frame:
Baseline (Days 1 and 56) and after 4 weeks of treatment (Days 28 and 84)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Nighttime Asthma Symptoms
units on a scaleRoflumilast Plus MontelukastPlacebo Plus Montelukast
Change From Baseline in Nighttime Asthma Symptoms-0.27 ± 0.053-0.17 ± 0.052
Statistical analysis
  • Roflumilast Plus Montelukast vs Placebo Plus Montelukast · ANCOVA · p = 0.217 (P-values were obtained using an ANCOVA model with treatment sequence, treatment period, and study treatment as fixed factors with Baseline Nighttime Asthma Symptoms measurement as the covariate.) · Ls mean difference: -0.09 · 95% CI -0.2426 to 0.0563

Adverse events

Collected over Baseline to the end of the study (Days 1-105). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roflumilast Plus Montelukast—0/61 (0%)5/61 (8.2%)
Placebo Plus Montelukast—0/62 (0%)0/62 (0%)
Most frequent other events
Most frequent other events
EventRoflumilast Plus MontelukastPlacebo Plus Montelukast
HeadacheNervous system disorders5/610/62

Baseline characteristics

Full analysis set: All randomized participants, analyzed according to the randomized treatment.

Age, Continuous
Age, Continuous(years)Roflumilast Plus Montelukast, Then Placebo Plus MontelukastPlacebo Plus Montelukast, Then Roflumilast Plus MontelukastTotal
Mean50.3 ± 13.8050.0 ± 14.1050.1 ± 13.84
Age, Customized
Age, Customized(participants)Roflumilast Plus Montelukast, Then Placebo Plus MontelukastPlacebo Plus Montelukast, Then Roflumilast Plus MontelukastTotal
< 65 years272754
≥ 65 years5510
Gender
Gender(Participants)Roflumilast Plus Montelukast, Then Placebo Plus MontelukastPlacebo Plus Montelukast, Then Roflumilast Plus MontelukastTotal
Female212041
Male111223
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Roflumilast Plus Montelukast, Then Placebo Plus MontelukastPlacebo Plus Montelukast, Then Roflumilast Plus MontelukastTotal
Black or African American303
White293261
Region of Enrollment
Region of Enrollment(participants)Roflumilast Plus Montelukast, Then Placebo Plus MontelukastPlacebo Plus Montelukast, Then Roflumilast Plus MontelukastTotal
South Africa161127
Germany81220
Hungary8917
Height
Height(cm)Roflumilast Plus Montelukast, Then Placebo Plus MontelukastPlacebo Plus Montelukast, Then Roflumilast Plus MontelukastTotal
Mean163.7 ± 8.47168.3 ± 10.68166.0 ± 9.85
Weight
Weight(kg)Roflumilast Plus Montelukast, Then Placebo Plus MontelukastPlacebo Plus Montelukast, Then Roflumilast Plus MontelukastTotal
Mean79.06 ± 18.70885.16 ± 17.49182.11 ± 18.227
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Roflumilast Plus Montelukast, Then Placebo Plus MontelukastPlacebo Plus Montelukast, Then Roflumilast Plus MontelukastTotal
Mean29.53 ± 7.10530.06 ± 5.60529.79 ± 6.354

1 further baseline measures are reported on the registry.

08

Study locations

13 sites
  • Berlin, Germany
  • Grosshansdorf, Germany
  • Hamburg, Germany
  • Hannover, Germany
  • Mainz, Germany
  • Schwerin, Germany
  • Budapest, Hungary
  • Nyiregyhaza, Hungary
  • Szarvas, Hungary
  • Torokbalint, Hungary
  • Bloemfontein, South Africa
  • Cape Town, South Africa
  • Pretoria, South Africa
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2013
First posted
Jan 10, 2013
Start
Feb 2013
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Jul 8, 2015
Last update
Feb 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01765192
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 10, 2013
Start date
Feb 2013
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Jul 8, 2015
Last update
Feb 1, 2017

Study contacts

AstraZeneca AstraZeneca
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Roflumilast · Montelukast

Start the discussion